Skip to main content
Phase I Trial of Super-Selective Intra-Arterial Infusion of Cetuximab (Erbitux) with or without Radiation Therapy for Treatment of Unresectable Recurrent Cancer of Head & Neck (Squamous Cell Carcinoma, incl Nasopharyngeal Cancer, Adenoid Cystic Carcinoma)
Sponsor: Northwell Health

The purpose of this study is to evaluate the safety of administering up to two doses of cetuximab into the patients artery for the treatment of recurrent head and neck cancer (subtypes squamous cell carcinoma including nasopharyngeal cancer or adenoid cystic carcinoma). This study aims to determine the best tolerated dosage of cetuximab administered into arteries by gradually increasing the dosage of 100mg/m2, if it’s determined to be safe to increase. Through our novel delivery method called super-selective intra-arterial infusion, we hope to allow the delivery of a higher dose of cetuximab to the patient’s tumor, while limiting exposure of the drug to the rest of the patient’s body. full clinical trial description



Lenox Hill Hospital
100 E 77th StNew York, NY 10075